AU2020226723B2 - Crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)- - Google Patents

Crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)- Download PDF

Info

Publication number
AU2020226723B2
AU2020226723B2 AU2020226723A AU2020226723A AU2020226723B2 AU 2020226723 B2 AU2020226723 B2 AU 2020226723B2 AU 2020226723 A AU2020226723 A AU 2020226723A AU 2020226723 A AU2020226723 A AU 2020226723A AU 2020226723 B2 AU2020226723 B2 AU 2020226723B2
Authority
AU
Australia
Prior art keywords
crystalline form
compound
disease
temperature
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
AU2020226723A
Other languages
English (en)
Other versions
AU2020226723A1 (en
Inventor
Robert Michael Geertman
Kristof Leonard KIMPE
Carina Leys
Haojuan WEI
Peng Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of AU2020226723A1 publication Critical patent/AU2020226723A1/en
Application granted granted Critical
Publication of AU2020226723B2 publication Critical patent/AU2020226723B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2020226723A 2019-02-22 2020-02-20 Crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)- Expired - Fee Related AU2020226723B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2019/075834 2019-02-22
CN2019075834 2019-02-22
PCT/EP2020/054485 WO2020169736A1 (en) 2019-02-22 2020-02-20 Crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-n-(2-(trifluoromethyl)pyridin-4-yl)-1h-pyrazole-4-carboxamide monohydrate

Publications (2)

Publication Number Publication Date
AU2020226723A1 AU2020226723A1 (en) 2021-08-19
AU2020226723B2 true AU2020226723B2 (en) 2025-01-23

Family

ID=69723907

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020226723A Expired - Fee Related AU2020226723B2 (en) 2019-02-22 2020-02-20 Crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-

Country Status (21)

Country Link
US (1) US12269813B2 (https=)
EP (1) EP3927696B1 (https=)
JP (1) JP2022523368A (https=)
KR (1) KR20210131371A (https=)
CN (1) CN113474339B (https=)
AU (1) AU2020226723B2 (https=)
BR (1) BR112021016400A2 (https=)
CA (1) CA3129623A1 (https=)
EA (1) EA202192320A1 (https=)
EC (1) ECSP21067828A (https=)
ES (1) ES2966132T3 (https=)
IL (1) IL285675A (https=)
JO (1) JOP20210227A1 (https=)
MA (1) MA55019A (https=)
MX (1) MX2021010133A (https=)
PE (1) PE20212067A1 (https=)
PH (1) PH12021552018A1 (https=)
SG (1) SG11202108909SA (https=)
TW (1) TW202045495A (https=)
UY (1) UY38592A (https=)
WO (1) WO2020169736A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物
ES2949871T3 (es) 2019-04-11 2023-10-03 Janssen Pharmaceutica Nv Anillos de piridina que contienen derivados como inhibidores de MALT1
JP2023539729A (ja) 2020-08-21 2023-09-19 ヤンセン ファーマシューティカ エヌ．ベー． Ｍａｌｔ１阻害剤の非晶質形態及びその製剤
JP2024508890A (ja) 2021-03-03 2024-02-28 ヤンセン ファーマシューティカ エヌ．ベー． 治療有効用量のｍａｌｔ１阻害剤ｊｎｊ－６７８５６６３３（１－（１－オキソ－１，２－ジヒドロイソキノリン－５－イル）－５－（トリフルオロメチル）－ｎ－（２－（トリフルオロメチル）ピリジン－４－イル）－１ｈ－ピラゾール－４－カルボキサミド）を使用して状態を治療する方法
EP4301365A1 (en) 2021-03-03 2024-01-10 Janssen Pharmaceutica NV Combination therapy using a malt1 inhibitor and a btk inhibitor
KR20240046170A (ko) 2021-08-09 2024-04-08 얀센 파마슈티카 엔브이 B-세포 악성종양의 치료에 사용하기 위한 조성물
AU2024357109A1 (en) 2023-10-06 2026-03-12 Ionctura Sa Combination of roginolisib with a malt1-gls inhibitor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018119036A1 (en) * 2016-12-21 2018-06-28 Janssen Biotech, Inc. Pyrazole derivatives as malt1 inhibitors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2522994C (en) 2003-04-30 2012-09-25 Agensys, Inc. Nucleic acids and corresponding proteins entitled 109p1d4 useful in treatment and detection of cancer
ES2336625T3 (es) * 2006-03-22 2010-04-14 Vertex Pharmaceuticals Incorporated Inhibidores de la proteina quinasa c-met para el tratamiento de trastornos proliferativos.
WO2008092292A1 (en) 2007-01-17 2008-08-07 The Hong Kong University Of Science And Technology Isoquinolone compounds as subtype-selective agonists for melatonin receptors mt1 and mt2
WO2011036885A1 (ja) * 2009-09-25 2011-03-31 武田薬品工業株式会社 複素環化合物
US20120071497A1 (en) 2010-06-03 2012-03-22 Pharmacyclics, Inc. Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
CN107898791A (zh) 2010-06-03 2018-04-13 药品循环有限责任公司 布鲁顿酪氨酸激酶(btk)抑制剂的应用
JP5984801B2 (ja) 2010-06-22 2016-09-06 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ ４−ヒドロキシピリジン類の製造方法
KR20150020228A (ko) * 2012-05-31 2015-02-25 에프. 호프만-라 로슈 아게 아미노퀴나졸린 및 피리도피리미딘 유도체
ES2738695T3 (es) 2014-05-28 2020-01-24 Novartis Ag Nuevos Derivados de Pirazolo Pirimidina y su uso como inhibidores de MALT1
CA2956550A1 (en) 2014-08-08 2016-02-11 Pharmacyclics Llc Bruton's tyrosine kinase inhibitor combinations and uses thereof
WO2016209688A1 (en) * 2015-06-24 2016-12-29 University Of Florida Research Foundation, Incorporated Compositions for the treatment of cancer and uses thereof
WO2017081641A1 (en) 2015-11-13 2017-05-18 Novartis Ag Novel pyrazolo pyrimidine derivatives
US10882841B2 (en) 2016-03-01 2021-01-05 University Of Maryland, Baltimore Wnt signaling pathway inhibitors for treatments of disease
US20200009135A1 (en) 2017-02-01 2020-01-09 Medivir Ab Therapeutic applications of malt1 inhibitors
MX2020006808A (es) 2017-12-28 2020-12-11 Massachusetts Gen Hospital Ubicar al complejo de signalosoma cbm induce a las celulas t reguladoras inflamar al microambiente tumoral.
US20210001733A1 (en) 2018-02-23 2021-01-07 Industrieanlagen-Betriebsgesellschaft Mbh Device for generating a magnetic field, in particular for an inductive charging system, and primary device of an inductive charging system for dynamically charging vehicles
WO2021138298A1 (en) 2019-12-30 2021-07-08 Rheos Medicines, Inc. Malt1 modulators and uses thereof
JP2023539729A (ja) * 2020-08-21 2023-09-19 ヤンセン ファーマシューティカ エヌ．ベー． Ｍａｌｔ１阻害剤の非晶質形態及びその製剤

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018119036A1 (en) * 2016-12-21 2018-06-28 Janssen Biotech, Inc. Pyrazole derivatives as malt1 inhibitors

Also Published As

Publication number Publication date
US12269813B2 (en) 2025-04-08
MX2021010133A (es) 2021-09-23
CA3129623A1 (en) 2020-08-27
AU2020226723A1 (en) 2021-08-19
ECSP21067828A (es) 2021-11-18
SG11202108909SA (en) 2021-09-29
US20220127249A1 (en) 2022-04-28
PH12021552018A1 (en) 2022-09-19
CN113474339B (zh) 2025-02-25
JP2022523368A (ja) 2022-04-22
BR112021016400A2 (pt) 2021-10-13
EP3927696A1 (en) 2021-12-29
PE20212067A1 (es) 2021-10-26
EP3927696B1 (en) 2023-10-18
UY38592A (es) 2020-08-31
ES2966132T3 (es) 2024-04-18
IL285675A (en) 2021-10-31
MA55019A (fr) 2021-12-29
EP3927696C0 (en) 2023-10-18
CN113474339A (zh) 2021-10-01
JOP20210227A1 (ar) 2021-08-18
EA202192320A1 (ru) 2021-11-16
WO2020169736A1 (en) 2020-08-27
KR20210131371A (ko) 2021-11-02
TW202045495A (zh) 2020-12-16

Similar Documents

Publication Publication Date Title
AU2020226723B2 (en) Crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-
CN105793245B (zh) 药物化合物
EP4412719A1 (en) Combination therapies of kras g12d inhibitors with shp-2 inhibitors
TW200911817A (en) Polycyclic guanine derivatives and methods of use thereof
US11918585B2 (en) Formulations of an AXL/MER inhibitor
CN110305140B (zh) 二氢吡咯并嘧啶类选择性jak2抑制剂
US20230331703A1 (en) Egfr inhibitors
TW202136263A (zh) 新穎 egfr 抑制劑
CA3175541A1 (en) Solid forms of (s)-6-(((1-(bicyclo[1.1.1]pentan-1-yl)-1h-1,2,3-triazol-4-yl)2-methyl-1-oxo-1,2- dihydroisoquinolin-5-yl)methyl)))amino)8-chloro-(neopentylamino)quinoline-3-carb onitrile a cot inhibitor compound
ES2379734T3 (es) Derivado de pirrol o sal del mismo
CA3152320A1 (en) Pharmaceutical compounds
CN116916922B (zh) (s,e)-4-(二甲胺基)-n-(3-(4-(2-羟基-1-苯乙胺基)-6-苯基呋喃并[2,3-d]嘧啶-5-基)苯基)丁-2-烯酰胺游离碱的晶型
HK40052643A (en) Crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-n-(2-(trifluoromethyl)pyridin-4-yl)-1h-pyrazole-4-carboxamide monohydrate
EA045924B1 (ru) Кристаллическая форма моногидрата 1-(1-оксо-1,2-дигидроизохинолин-5-ил)-5-(трифторметил)-n-(2-(трифторметил)пиридин-4-ил)-1h-пиразол-4-карбоксамида
WO2023154338A1 (en) Solid forms of a parp14 inhibitor
WO2008033513A1 (en) ISOXAZOLINE ALPHA 1a/1d ADRENORECEPTOR ANTAGONISTS
CN111138426B (zh) 吲唑类激酶抑制剂及其用途
CA3135309A1 (en) Isochromene derivatives as phosphoinositide 3-kinases inhibitors
TW201829398A (zh) 酪胺酸蛋白激酶調節劑、晶型及其用途
WO2023155760A1 (zh) 一种药物组合物及所含活性成分化合物的制备方法
HK40052420A (en) Formulations of an axl/mer inhibitor
HK40052420B (en) Formulations of an axl/mer inhibitor
HK1261832B (zh) 喹唑啉衍生物的盐的晶体

Legal Events

Date Code Title Description
MK25 Application lapsed reg. 22.2i(2) - failure to pay acceptance fee